The findings may help inform decisions about insulin therapy for patients with type 2 diabetes, for example, when minimizing weight gain or nocturnal hypoglycemia is a priority.
Expert panel recommends SGLT2 inhibitor or GLP-1 receptor agonist for patients with type 2 diabetes and CVD | ACP Diabetes Monthly
The American College of Cardiology's new decision pathway also calls for repeated HbA1c screening and detailed clinician-patient risk discussions for patients with cardiovascular disease (CVD) who are diagnosed with type 2 diabetes.
ACP has partnered with the American College of Cardiology to participate in the Diabetes Collaborative Registry, a national clinical diabetes registry and interdisciplinary collaboration designed to assess and improve the quality of a practice's
Task Force recommends screening for type 2 diabetes in overweight, obese adults | ACP Diabetes Monthly
The U.S. Preventive Services Task Force now recommends screening for abnormal blood glucose as part of cardiovascular risk assessment in overweight and obese adults ages 40 to 70 years.
Analysis finds several treatments for painful diabetic neuropathy more effective than placebo | ACP Diabetes Monthly
A large meta-analysis recently compared the effectiveness of pharmacological treatments for painful diabetic neuropathy.
Preoperative factors may help predict long-term weight outcomes after gastric bypass, study finds | ACP Diabetes Monthly
Only 3 factors were associated with greater long-term weight loss: preoperative insulin use, history of smoking, and use of 12 or more medications before surgery.
Patients who began taking tramadol were significantly more likely to be hospitalized for hypoglycemia than those prescribed codeine, a recent study found.
Patients at risk for diabetes or heart disease may want to choose their workout intensity based on health goals, according to a study.
Weight loss program may improve HbA1c more than typical diabetes nutrition counseling, study finds | ACP Diabetes Monthly
Patients participating in Weight Watchers program supplemented with diabetes education lost more weight than a control group by 3, 6, 9, and 12 months of follow-up.
Canagliflozin may not increase fracture risk in patients at low risk for fractures | ACP Diabetes Monthly
Although canagliflozin has been linked to decreased bone mineral density, patients with type 2 diabetes who initiated the drug had similar risk of a first fracture as those who started a glucagon-like peptide-1 receptor agonist.